MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the activity and the toxicity of capecitabine as
monotherapy in the treatment of platinum resistant or refractory ovarian cancer.